Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arovella Therapeutics Limited ( (AU:ALA) ) has provided an update.
Arovella Therapeutics has appointed Lachie Mallia as Company Secretary and Chief Financial Officer, effective 22 January 2026, replacing fellow Bio101 Financial Advisory director Tim Luscombe, who previously held the roles. Mallia, a director at Bio101 with extensive experience providing outsourced CFO, company secretarial and advisory services to healthcare companies, will oversee ASX communications on listing rule matters, bolstering Arovella’s governance and financial management as it advances its oncology cell therapy pipeline.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is an ASX-listed biotechnology company developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR19-iNKT cell therapy targeting CD19 and CD1d antigens across multiple cancer types, and the company is also pursuing solid tumour programs using CLDN18.2-targeting and IL-12-TM technologies.
Average Trading Volume: 969,187
Technical Sentiment Signal: Hold
Current Market Cap: A$105.7M
For detailed information about ALA stock, go to TipRanks’ Stock Analysis page.